Prof Giuseppe Saglio speaks to ecancer about the ‘Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study’ which was presented at the virtual ASH 2020 meeting.
Initially, he talks about what the Gimema cml study was about. Dr Saglio then explains what end-point this analysis evaluated.
Whilst highlighting the key results of this study he says that in this first analysis of this study different clinical behaviours were observed among Italian haematologists, who prevalently prescribed IMA to older patients, with more comorbidities, as compared to second genTKIs.
These differences explain a better OS for patients treated with second genTKIs vs IMA, however, the risk of death for CML related causes is quite similar between the two groups, all the differences being attributable to other causes of death.
In the end, he talks about how these results can impact the future treatment of these patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.